Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Epidemiology of echinocandin resistance in Candida
  • Published Date:
    Sep 21 2014
  • Source:
    Curr Fungal Infect Rep. 8(4):243-248.
Filetype[PDF-307.70 KB]

  • Alternative Title:
    Curr Fungal Infect Rep
  • Description:
    Echinocandins are the newest antifungal agents approved for use in treating | infections in the US. They act by interfering with 1,3-β-D-glucan synthase and therefore disrupt cell wall production and lead to | cell death. There is no intrinsic resistance to echinocandins among | species, and isolates from historic collections archived before the release of the echinocandins show no resistance. Resistance to the echinocandins remains low among most | species and ranges overall from 0-1%. Among isolates of |, the proportion of resistant isolates is higher and has been reported to be as high as 13.5% in at least one hospital. Antifungal resistance is due to specific amino acid mutations in the Fksp subunit(s) of the 1,3-β-D-glucan synthase protein which are localized to one of two hotspots. These mutations are being recognized in isolates from patients who have failed echinocandin therapy, and often lead to a poor outcome. While the future looks bright for the echinocandins against most | species, | remains a species of concern and resistance rates of | to the echinocandins should be monitored closely.

  • Pubmed ID:
  • Pubmed Central ID:
  • Document Type:
  • Collection(s):
  • Main Document Checksum:
No Related Documents.
You May Also Like: